Literature DB >> 25706704

Sorafenib for patients with differentiated thyroid cancer.

Pascaline Boudou-Rouquette1, Audrey Thomas-Schoemann2, Audrey Bellesoeur2, François Goldwasser2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25706704     DOI： 10.1016/S0140-6736(15)60054-X

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer.

Authors:  Yihebali Chi; Jianliang Yang; Sheng Yang; Yongkun Sun; Bo Jia; Yuankai Shi
Journal:  Chin J Cancer Res       Date:  2015-06       Impact factor: 5.087

2.  Inhibition of the Ras/Raf interaction and repression of renal cancer xenografts in vivo by an enantiomeric iridium(iii) metal-based compound.

Authors:  Li-Juan Liu; Wanhe Wang; Shi-Ying Huang; Yanjun Hong; Guodong Li; Sheng Lin; Jinglin Tian; Zongwei Cai; Hui-Min David Wang; Dik-Lung Ma; Chung-Hang Leung
Journal:  Chem Sci       Date:  2017-05-16       Impact factor: 9.825

Review 3.  Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.

Authors:  Audrey Bellesoeur; Edith Carton; Jerome Alexandre; Francois Goldwasser; Olivier Huillard
Journal:  Drug Des Devel Ther       Date:  2017-09-21       Impact factor: 4.162

Review 4.  A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma.

Authors:  Manuela Tiako Meyo; Jeanne Chen; Francois Goldwasser; Laure Hirsch; Olivier Huillard
Journal:  Ther Clin Risk Manag       Date:  2022-07-08       Impact factor: 2.755
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.